The Association of Electronic Cigarette Use With SARS-CoV-2 Infection and COVID-19 Disease Severity.

COVID-19 electronic cigarettes hospitalization infection vaping

Journal

Tobacco use insights
ISSN: 1179-173X
Titre abrégé: Tob Use Insights
Pays: United States
ID NLM: 101608659

Informations de publication

Date de publication:
2022
Historique:
received: 27 01 2022
accepted: 06 04 2022
entrez: 2 5 2022
pubmed: 3 5 2022
medline: 3 5 2022
Statut: epublish

Résumé

Although combustible cigarette use is an established risk factor for severe COVID-19 disease, there is conflicting evidence for the association of electronic cigarette use with SARS-CoV-2 infection and COVID-19 disease severity. Study participants were from the Kaiser Permanente Research Bank (KPRB), a biorepository that includes adult Kaiser Permanente members from across the United States. Starting in April 2020, electronic surveys were sent to KPRB members to assess the impact of the COVID-19 pandemic. These surveys collected information on self-report of SARS-CoV-2 infection and COVID-related risk factors, including electronic cigarette and combustible cigarette smoking history. We also used electronic health records data to assess COVID-19 diagnoses, positive PCR lab tests, hospitalizations, and death. We used multivariable Cox proportional hazards regression to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) comparing the risk of SARS-CoV-2 infection between individuals by e-cigarette use categories (never, former, and current). Among those with SARS-CoV-2 infection, we used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95% CIs comparing the odds of hospitalization or death within 30 days of infection between individuals by e-cigarette use categories. There were 126,475 individuals who responded to the survey and completed questions on e-cigarette and combustible cigarette use (48% response rate). Among survey respondents, 819 (1%) currently used e-cigarettes, 3,691 (3%) formerly used e-cigarettes, and 121,965 (96%) had never used e-cigarettes. After adjustment for demographic, behavioral, and clinical factors, there was no association with SARS-CoV-2 infection and former e-cigarette use (hazard ratio (HR) = 0.99; CI: 0.83-1.18) or current e-cigarette use (HR = 1.08; CI: 0.76-1.52). Among those with SARS-CoV-2 infection, there was no association with hospitalization or death within 30 days of infection and former e-cigarette use (odds ratio (OR) = 1.19; CI: 0.59-2.43) or current e-cigarette use (OR = 1.02; CI: 0.22-4.74). Our results suggest that e-cigarette use is not associated with an increased risk of SARS-CoV-2 infection or severe COVID-19 illness.

Sections du résumé

BACKGROUND BACKGROUND
Although combustible cigarette use is an established risk factor for severe COVID-19 disease, there is conflicting evidence for the association of electronic cigarette use with SARS-CoV-2 infection and COVID-19 disease severity.
METHODS METHODS
Study participants were from the Kaiser Permanente Research Bank (KPRB), a biorepository that includes adult Kaiser Permanente members from across the United States. Starting in April 2020, electronic surveys were sent to KPRB members to assess the impact of the COVID-19 pandemic. These surveys collected information on self-report of SARS-CoV-2 infection and COVID-related risk factors, including electronic cigarette and combustible cigarette smoking history. We also used electronic health records data to assess COVID-19 diagnoses, positive PCR lab tests, hospitalizations, and death. We used multivariable Cox proportional hazards regression to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) comparing the risk of SARS-CoV-2 infection between individuals by e-cigarette use categories (never, former, and current). Among those with SARS-CoV-2 infection, we used multivariable logistic regression to estimate adjusted odds ratios (ORs) and 95% CIs comparing the odds of hospitalization or death within 30 days of infection between individuals by e-cigarette use categories.
RESULTS RESULTS
There were 126,475 individuals who responded to the survey and completed questions on e-cigarette and combustible cigarette use (48% response rate). Among survey respondents, 819 (1%) currently used e-cigarettes, 3,691 (3%) formerly used e-cigarettes, and 121,965 (96%) had never used e-cigarettes. After adjustment for demographic, behavioral, and clinical factors, there was no association with SARS-CoV-2 infection and former e-cigarette use (hazard ratio (HR) = 0.99; CI: 0.83-1.18) or current e-cigarette use (HR = 1.08; CI: 0.76-1.52). Among those with SARS-CoV-2 infection, there was no association with hospitalization or death within 30 days of infection and former e-cigarette use (odds ratio (OR) = 1.19; CI: 0.59-2.43) or current e-cigarette use (OR = 1.02; CI: 0.22-4.74).
CONCLUSIONS CONCLUSIONS
Our results suggest that e-cigarette use is not associated with an increased risk of SARS-CoV-2 infection or severe COVID-19 illness.

Identifiants

pubmed: 35492220
doi: 10.1177/1179173X221096638
pii: 10.1177_1179173X221096638
pmc: PMC9044777
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1179173X221096638

Informations de copyright

© The Author(s) 2022.

Déclaration de conflit d'intérêts

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Eur Respir J. 2020 Jul 16;56(1):
pubmed: 32430427
Drug Alcohol Depend. 2021 Apr 1;221:108590
pubmed: 33631546
Prev Med Rep. 2020 Dec;20:101254
pubmed: 33257909
J Adolesc Health. 2020 Oct;67(4):519-523
pubmed: 32798097
J Gen Intern Med. 2020 Jul;35(7):2130-2135
pubmed: 32246394
Respir Res. 2019 Dec 18;20(1):267
pubmed: 31847850
Tob Induc Dis. 2021 Feb 04;19:09
pubmed: 33551713
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211024391
pubmed: 34109870

Auteurs

Andrea N Burnett-Hartman (AN)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.

Shauna Goldberg Scott (S)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

J David Powers (JD)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Morgan N Clennin (MN)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Jason A Lyons (JA)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Mark Gray (M)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Heather Spencer Feigelson (HS)

Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA.

Classifications MeSH